Wearable data acquisition devices including sensors for detecting physiological signals are used to detect and measure various parameters pertaining to the health of the wearer. Through the use of algorithms, the data detected and measured by said sensors are processed to make inferences used to monitor the health of the wearer. An signal to noise ratio (SNR) calculation is used as a component of the sensitivity analysis of an algorithm. For example, a sleep algorithm will select a block of data, the SNR calculation will be done, with the average quality of the signal as result. The value associated with said signal quality may then be subjected to sensitivity analysis, which will yield a sleep accuracy value which, in turn, is indicative of the minimum signal quality which is required.

Embodiments provide devices, systems and methods for measuring a gastric emptying (GE) parameter (GEP). Many embodiments provide a swallowable capsule having three electrodes one covered by a coating which remains in the stomach but is degraded in the small intestine (SI). The electrodes are coupled to circuitry such that when the capsule is in the stomach, current flow occurs between the first two electrodes generating a first signal and in the SI current flow occurs between the second and now uncovered third electrode generating a second signal. These two signals can be transmitted and analyzed externally or by an internal controller to determine a GEP e.g., GE time. The patient may wear an external device configured to receive and analyze the signals to determine GE time. Embodiments of the invention may be used to diagnose gastroparesis and provide patient's information on when to eat meals or administer insulin after eating.

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

A header-less implantable medical device, system and method are provided. The device includes an electronics module including circuitry, a battery, a receptacle assembly having an interior chamber and a receptable inlet configured to receive a lead connector assembly. A device housing has a case body that includes side walls and a peripheral edge that defines a single common chamber. The electronics module, battery and receptacle assembly are provided within the single common chamber. A connector opening is provided in the case body and joined to the receptacle inlet to form a passage through the case body into the interior chamber of the receptacle assembly.

Ingestible radio frequency identification (RFID) tags are disclosed. A system embodiment includes, but is not limited to, an RFID tag including a flexible substrate foldable between a planar configuration and a tubular configuration, a conductive element disposed on the flexible substrate, and an RFID tag chip electrically coupled with the conductive element; a capsule structured and dimensioned for ingestion by a biological subject, the capsule including a shell structured and dimensioned to enclose a medication for the biological subject simultaneously with the RFID tag when the flexible substrate is in the tubular configuration, but not when the flexible substrate is in the planar configuration; and a pH switch structure coupled to an exterior surface of the capsule, the pH switch configured to deactivate the RFID tag in a first configuration and to permit activation of the RFID tag in a second configuration within the biological subject.

Systems for liquid biopsy and/or drug delivery may include a capsule endoscope and a tether coupled to the capsule endoscope. The tether may include a flexible member with a lumen in fluidic communication with a port configured to permit passage of fluid, and the port may be, for example, on the capsule endoscope or the tether. In methods for liquid biopsy and/or drug delivery, the capsule endoscope may be advanced into a gastrointestinal tract of a patient, and navigated to a region of interest, where a patient sample may be withdrawn and/or a therapeutic substance may be administered through the lumen (e.g., through the port).

The present disclosure relates to an apparatus, system and method for inserting one or more probes into a subjects body for one or more purposes of acquiring physiological data or delivering a treatment into the subjects body.

The disclosure provides a diagnosis and treatment integrated soft medical robot for gastrointestinal endoscopy, including a robot body, a camera, illumination devices, a flexible dielectric elastomer actuator, air cylinders, linear motors, a controller and external hoses. The robot body is a multichannel hose, and includes a central channel and circumferential channels, the central channel is configured to accommodate conducting wires and signal wires, the circumferential channels include at least three microfluid channels. The linear motors control fluid pressures in the microfluid channels by driving piston rods of the air cylinders so that the robot body steers through being driven by fluid. The camera performs real-time image acquisition. The controller controls the flexible dielectric elastomer actuator to capture a target. The disclosure realizes the real-time image acquisition on a digestive tract, particularly a lesion, and can integrally and fast complete diagnosis and treatment.

A method of managing a disease and an apparatus performing the same are provided. The method of managing livestock disease includes receiving biometric information of livestock from a biosensor capsule settled in a body of the livestock, detecting a singular point deviating from a reference value, based on the biometric information, monitoring a health state by increasing a disease probability of the livestock when the singular point is detected, and detecting a disease by determining an abnormality in the health state of the livestock when the disease probability of the livestock is a first threshold value or more. An animal subject suspected of reproductive disorders (ovarian cyst) may be rapidly detected, and intensive care (veterinary examination and hormone prescription) may be provided to the farm, thereby increasing productivity of the farm.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.